Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 6/20 | 0.34 |
| ▸ | ARG2 | P78540 | 5/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899581 | 0.89 | GRM2 (0.33) | GRM5GRM1GRM2 | |
| SCHEMBL5899778 | 0.82 | ARG1 (0.31) | ARG1ARG2ALDH1A1 | |
| SCHEMBL5899569 | 0.81 | ALDH1A1 (0.34) | ARG1ARG2SLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL3546456 | 0.81 | GRM2 (0.35) | SLC6A2SLC6A4GRM5GRM1GRM2 | |
| SCHEMBL11214435 | 0.80 | ALOX5 (0.40) | ALDH1A1ALOX5 | |
| SCHEMBL5899606 | 0.78 | CPB2 (0.31) | — | |
| SCHEMBL5899637 | 0.78 | MAPT (0.35) | SLC1A2 | |
| SCHEMBL5899650 | 0.77 | SLC6A2 (0.33) | SLC6A2SLC6A4GRM5GRM1GRM2 | |
| SCHEMBL28747541 | 0.74 | GRM2 (0.55) | ARG1ARG2GRM5GRM1GRM2 | |
| SCHEMBL11029945 | 0.74 | SLC6A2 (0.37) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1764634-A | Cyclopropyl beta-amino acid derivatives | WARNER LAMBERT CO (US) | 2006-04-26 | — | — | CN | claimed |
| US-7030267-B2 | Cycloproply β-amino acid derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2006-04-18 | — | — | US | claimed |
| EP-1592661-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004065361-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | claimed |
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | SCHWARZ JACOB BRADLEY (US) | 2004-07-29 | — | — | US | claimed |
| CN-1764634-A | Cyclopropyl beta-amino acid derivatives | WARNER LAMBERT CO (US) | 2006-04-26 | — | — | CN | disclosed |
| US-7030267-B2 | Cycloproply β-amino acid derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | SCHWARZ JACOB BRADLEY (US) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | CACNA1S, CACNA1D, CACNA1B | ARG1 2810/4885ARG2 1542/4885SLC1A2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.